Resources
5 Results (showing 1 - 5)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”
Posted 12/9/2020 (updated 4/3/2024)
Detoxification is the process of taking a person off an opioid on which he or she is physically dependent. The detoxification process can be fast or slow. This article describes the advantages and disadvantages of medically supervised withdrawal programs.
Posted 5/12/2020 (updated 3/28/2024)
The Clinical Opiate Withdrawal Scale is an 11-item scale designed to be administered by a clinician.
Posted 5/12/2020 (updated 3/28/2024)
The CIWA-Ar assessment for monitoring withdrawal symptoms requires approximately 5 minutes to administer. The maximum score is 67. Patients scoring less than 10 do not usually need additional medication for withdrawal.